Abstract
Precision oncology with next-generation sequencing has begun in Japan from June 2019. Cancer gene panel tests are covered by national health insurance for all patients with recurrent and refractory solid tumor including metastatic breast cancer (mBC), Recently, the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) recommend that no current indication for tumor multigene NGS in breast cancer. But from the perspective of clinical research centers, and considering the high number of level II alterations, it is important to include mBC patients in molecular screening programmes and include them in trials testing targeted therapies matched to genomic alterations, such as AKT1E17K, PTEN, ERBB2 mutations, ESR1 and NF1 mutations. In this presentation, I reviewed our experience for mBC patients undergoing cancer gene panel tests at our hospital. Furthermore, I will discuss the clinical utility of using NGS and how this technology should be used in metastatic breast cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
